TYRA - CONSENSUS CO - Tyra Biosciences, Inc.

Tyra Biosciences, Inc. (TYRA) develops high-precision oncology drugs, targeting rare genetic mutations to ensure stable demand. This chart on GURU.Markets illustrates the price action of the asset, which currently stands at 47.61. Production capacities are fully utilized, and equipment reliability guarantees adherence to deadlines. Business growth is driven by patents, selective FGFR inhibitors, and efficient capital raising.

This indicator reflects the weighted average fair value estimate of the stock based on professional analyst forecasts. The historical trend of the consensus target price visualizes market expectations regarding the future capitalization of the business. The calculation is based on a combination of fundamental factors and macroeconomic variables, determining the growth potential of the quotes. For Tyra Biosciences, Inc. (TYRA), the target price dynamics correlate with the success of pure research and development. The startup's environmental profile is limited to reagent disposal, which minimizes operational risks.